Why Myriad Genetics, Inc. Popped Today

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Myriad Genetics, (NASDAQ: MYGN  ) soared 13% today after the Centers for Medicare & Medicaid Services updated pricing for the sequencing of the BRCA1 and BRCA2 genes.

So what: Myriad shares had pulled back in recent weeks on concerns about increasing competition, but Medicare's decision to lift final BRCA reimbursement levels is helping ease those worries. In fact, Credit Suisse upgraded Myriad to neutral, while Jefferies boosted its price target on the stock to $33 (from $30) on today's news, suggesting that Wall Street's becoming a bit more comfortable with the company's margins going forward. 

Now what: According to Jefferies, Myriad's risk/reward trade-off, while still not compelling, is much improved. Jefferies analyst Brandon Couillard said:

In a surprise move, CMS revised the final NLA for BRCA testing to ~$2,200 (+52% from prior interim price) following a public comment period. We are raising our FY14 EPS forecast to $2.17 (from $2.12) to account for the new CMS reality in 4Q14. Our PT moves to $33 (from $30) on higher intermediate-term cash flow forecasts.

When you couple Myriad's hot stock price with the competitive headwinds still facing it, however, I'd wait for a wider margin of safety before jumping in.  

3 stocks to own for the rest of your life
As every savvy investor knows, Warren Buffett didn't make billions by betting on half-baked stocks. He isolated his best few ideas, bet big, and rode them to riches, hardly ever selling. You deserve the same. That's why our CEO, legendary investor Tom Gardner, has permitted us to reveal The Motley Fool's 3 Stocks to Own Forever. These picks are free today! Just click here now to uncover the three companies we love. 


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2900174, ~/Articles/ArticleHandler.aspx, 7/22/2014 6:10:47 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement